NASH Fitness Intervention in Thrombosis Trial (NASHFit)
1 other identifier
interventional
28
1 country
1
Brief Summary
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. The most advanced forms of NAFLD are associated with increased liver-related mortality and lower overall survival. The current standard of care for NAFLD is lifestyle changes through diet and exercise. The human genome and regulation of gene expression is influenced by physical activity. NAFLD is a prothrombotic state with derangements in all three phases of hemostasis leading to clinically important clotting events. Exercise can improve coagulation in healthy persons. In this proposal, we seek to begin a line of work to answer the question "Can lifestyle changes effectively mitigate the increased risk of clotting in patients with NAFLD?" focusing initially on the at-risk population genetically susceptible to advanced disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 23, 2018
CompletedFirst Posted
Study publicly available on registry
May 8, 2018
CompletedStudy Start
First participant enrolled
June 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 24, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 24, 2021
CompletedResults Posted
Study results publicly available
February 3, 2023
CompletedFebruary 3, 2023
January 1, 2023
2.8 years
April 23, 2018
January 14, 2022
January 31, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
PAI-1 Level
Change in fibrinolysis as indicated by PAI-1 level was calculated by taking the difference of measurements at baseline and 5 months.
5 months
Secondary Outcomes (11)
Change in Von Williebrand Factor (vWF)
5 months
Change in Protein S
5 months
Change in Factor VIII
5 months
Change in Fibrinogen
5 months
Change in Antithrombin
5 months
- +6 more secondary outcomes
Study Arms (2)
Standard of Care
NO INTERVENTIONSubjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
Aerobic Exercise
EXPERIMENTALSubjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
Interventions
Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
Eligibility Criteria
You may qualify if:
- Lack of secondary causes of hepatic fat accumulation:
- Significant alcohol consumption (\<21 drinks/week for men and \<14 drinks/week for women) Chronic hepatitis C Wilson disease Lipodystrophy Parenteral nutrition Long-term use of steatogenic medications (mipomersen, lomitapide, amiodarone, methotrexate, tamoxifen, corticosteroids) Monogenic hereditary disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Penn State Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
Related Publications (2)
Channapragada T, Batra S, Hummer BL, Chinchilli VM, Huang D, Loomba R, Schreibman IR, Stine JG. Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index. Dig Dis Sci. 2025 Sep 3. doi: 10.1007/s10620-025-09361-9. Online ahead of print.
PMID: 40900364DERIVEDMotz V, Faust A, Dahmus J, Stern B, Soriano C, Stine JG. Utilization of a Directly Supervised Telehealth-Based Exercise Training Program in Patients With Nonalcoholic Steatohepatitis: Feasibility Study. JMIR Form Res. 2021 Aug 17;5(8):e30239. doi: 10.2196/30239.
PMID: 34402795DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Possible limitations include the sample size, lack of allocation concealment, study population largely of early-stage NASH that was also predominantly non-Hispanic white, lack of histologic endpoint, lack of long-term clinical outcomes and inability to show global changes in hemostasis with TEG.
Results Point of Contact
- Title
- Dr. Jonathan Stine
- Organization
- The Penn State College of Medicine
Study Officials
- PRINCIPAL INVESTIGATOR
Jonathan Stine, MD
Milton S. Hershey Medical Center
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor Medicine
Study Record Dates
First Submitted
April 23, 2018
First Posted
May 8, 2018
Study Start
June 1, 2018
Primary Completion
March 24, 2021
Study Completion
March 24, 2021
Last Updated
February 3, 2023
Results First Posted
February 3, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will not share